|
Delayed
Nasdaq
15:28:27 26/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 2.640 USD | -1.49% |
|
+1.14% | -69.83% |
Company Valuation: Atossa Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 202.6 | 66.92 | 110.3 | 118.8 | 76.21 | 26.74 | - | - |
| Change | - | -66.97% | 64.77% | 7.71% | -35.83% | -64.91% | - | - |
| Enterprise Value (EV) | 202.6 | 66.92 | 110.3 | 118.8 | 76.21 | 26.74 | 26.74 | 26.74 |
| Change | - | -66.97% | 64.77% | 7.71% | -35.83% | -64.91% | 0% | 0% |
| P/E | -8.89x | -2.52x | -3.67x | -4.72x | -2.19x | -0.7x | -0.85x | 0.99x |
| PBR | 1.47x | 0.57x | 1.22x | 1.69x | 1.92x | - | - | - |
| PEG | - | -0.2x | -0.3x | 0.3x | -0.1x | 0.14x | 0x | -0x |
| Capitalization / Revenue | - | - | - | - | - | - | - | 0.23x |
| EV / Revenue | - | - | - | - | - | - | - | 0.23x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -0.75x | -0.7x | 0.54x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.7 | -3.15 | -3.6 | -3 | -4.04 | -3.84 | -3.143 | 2.715 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - | 118.7 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -20.52 | -27.69 | -31.38 | -27.62 | -37.14 | -35.88 | -38.03 | 49.46 |
| Net income 1 | -20.61 | -26.96 | -30.09 | -25.5 | -34.77 | -34.89 | -38.03 | 49.46 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 24.000 | 7.927 | 13.200 | 14.161 | 8.850 | 2.680 | 2.680 | 2.680 |
| Nbr of stocks (in thousands) | 8,442 | 8,442 | 8,354 | 8,387 | 8,611 | 9,979 | - | - |
| Announcement Date | 28/02/22 | 22/03/23 | 01/04/24 | 25/03/25 | 25/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.7x | - | - | - | 26.74M | |
| 34.87x | 6.21x | 18.47x | 0.92% | 51.65B | |
| -21.73x | 287.37x | -22.58x | -.--% | 45.31B | |
| 33.41x | 3.25x | 14.01x | -.--% | 42.7B | |
| 49.3x | 5.73x | 31.35x | -.--% | 42.79B | |
| 28.8x | 8.7x | 21.99x | 0.4% | 32.87B | |
| 34.92x | 5.73x | 26.03x | -.--% | 17.14B | |
| 24.7x | 2.14x | 9.25x | 1.09% | 15.01B | |
| 79.62x | 4.17x | 16.19x | -.--% | 14.21B | |
| Average | 29.24x | 40.41x | 14.34x | 0.3% | 29.08B | |
| Weighted average by Cap. | 28.28x | 54.27x | 13.02x | 0.29% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ATOS Stock
- Valuation Atossa Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
